Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 17:12:675307.
doi: 10.3389/fimmu.2021.675307. eCollection 2021.

Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study

Affiliations

Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study

Klaus Berek et al. Front Immunol. .

Abstract

Background: Reports on typical routine cerebrospinal fluid (CSF) findings are outdated owing to novel reference limits (RL) and revised diagnostic criteria of Multiple Sclerosis (MS).

Objective: To assess routine CSF parameters in MS patients and the frequency of pathologic findings by applying novel RL.

Methods: CSF white blood cells (WBC), CSF total protein (CSF-TP), CSF/serum albumin quotient (Qalb), intrathecal synthesis of immunoglobulins (Ig) A, M and G, oligoclonal IgG bands (OCB) were determined in patients with clinically isolated syndrome (CIS) and MS.

Results: Of 541 patients 54% showed CSF pleocytosis with a WBC count up to 40/μl. CSF cytology revealed lymphocytes, monocytes and neutrophils in 99%, 41% and 9% of patients. CSF-TP and Qalb were increased in 19% and 7% applying age-corrected RL as opposed to 34% and 26% with conventional RL. Quantitative intrathecal IgG, IgA and IgM synthesis were present in 65%, 14% and 21%; OCB in 95% of patients. WBC were higher in relapsing than progressive MS and predicted, together with monocytes, the conversion from CIS to clinically definite MS. Intrathecal IgG fraction was highest in secondary progressive MS.

Conclusions: CSF profile in MS varies across disease courses. Blood-CSF-barrier dysfunction and intrathecal IgA/IgM synthesis are less frequent when the novel RL are applied.

Keywords: albumin quotient; cerebrospinal fluid; cytology; diagnosis; immunoglobulin synthesis; multiple sclerosis; total protein; white blood cells.

PubMed Disclaimer

Conflict of interest statement

KB has participated in meetings sponsored by and received travel funding from Roche and Biogen. GB has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene, Lilly, Merck, Novartis, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene, Merck, Novartis, Roche and Teva. MA received speaker honoraria and/or travel grants from Biogen, Merck, Novartis and Sanofi. FP has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, Celgene and Roche. Her institution has received research grants from Roche. AZ has participated in meetings sponsored by, received speaking honoraria or travel funding from Biogen, Merck, Sanofi-Genzyme and Teva. TB has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Biogen, Biologix, Bionorica, Celgene, Eisei, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme, Teva, UCB. His institution has received financial support in the past 12 months by unrestricted research grants (Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Aventis, Teva. FD has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Almirall, Alexion, Biogen, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and TEVA ratiopharm. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders). HH has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva, and received honoraria for acting as consultant for Teva and Biogen.

Figures

Figure 1
Figure 1
Flowchart of patients included in the study. CIS, clinically isolated syndrome; FU, follow-up; PPMS, primary progressive MS; RBC, red blood cell; RRMS, relapsing remitting MS; SPMS, secondary progressive MS.
Figure 2
Figure 2
Routine CSF parameters in different MS disease courses. (A) Frequency of elevated WBC count (≥5/μl) is higher in relapsing than progressive MS. (B) Median WBC count is higher in relapsing than progressive MS. (C) Intrathecal IgG fraction is higher in secondary progressive than relapsing MS. (D) Frequency of intrathecal IgA and IgM synthesis is lower according to Auer & Hegen than Reiber formula. (E, F) Frequency of CSF-restricted OCB is highest in definite MS. Group comparisons were performed by Mann-Whitney-U test or Pearson Chi-squared test. P values (marked as p*) were corrected for multiple comparisons after Bonferroni. CIS, clinically isolated syndrome; CSF, cerebrospinal fluid; DIS, dissemination in space; dissemination in time; IF, intrathecal fraction; Ig, immunoglobulin; MRI, magnetic resonance imaging; MS, multiple sclerosis; OCB, oligoclonal bands; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.

Similar articles

Cited by

References

    1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. . Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. Lancet Neurol (2018) 17(2):162–73. 10.1016/S1474-4422(17)30470-2 - DOI - PubMed
    1. Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Rio J, et al. . The Value of Oligoclonal Bands in the Multiple Sclerosis Diagnostic Criteria. Brain (2018) 141(4):1075–84. 10.1093/brain/awy006 - DOI - PubMed
    1. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. . Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis: A Consensus Statement. Arch Neurol (2005) 62(6):865–70. 10.1001/archneur.62.6.865 - DOI - PubMed
    1. Reiber H, Ungefehr S, Jacobi C. The Intrathecal, Polyspecific and Oligoclonal Immune Response in Multiple Sclerosis. Mult Scler (1998) 4(3):111–7. 10.1177/135245859800400304 - DOI - PubMed
    1. Tourtellotte WW. The Cerebrospinal Fluid in Multiple Sclerosis. Handb Clin Neurol (1985) 47:79–130.